drugset
Drugs / TSND-201
last change Jun 2026 re-read 3 minutes ago

TSND-201

Developed for
post-traumatic stress disorder
Investigated by
Transcend Therapeutics

Trials 2

today NCT07670702 · Ph 3 NCT07456696 · Ph 3
202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT07670702 Jun 2026 → Dec 2028 expected post-traumatic stress disorder Transcend Therapeutics Enrolling by invitation No outcome recorded
Phase 3 NCT07456696 Apr 2026 → Dec 2027 expected post-traumatic stress disorder Transcend Therapeutics Recruiting No outcome recorded

Press releases naming this drug 16 releases

DateIssuerRelease
2026-04-27 Transcend Therapeutics Transcend Therapeutics Receives FDA National Priority Voucher for TSND-201 in PTSD transcendtherapeutics.com ↗
2026-02-18 Transcend Therapeutics IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD transcendtherapeutics.com ↗
2025-09-02 Transcend Therapeutics New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology transcendtherapeutics.com ↗
2025-05-27 Transcend Therapeutics TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust, and Long-Lasting Activity in Phase 2 transcendtherapeutics.com ↗
2025-05-27 Transcend Therapeutics TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder transcendtherapeutics.com ↗
2025-05-27 Transcend Therapeutics Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD transcendtherapeutics.com ↗
2025-03-31 Transcend Therapeutics Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD transcendtherapeutics.com ↗
2024-12-10 Transcend Therapeutics TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study transcendtherapeutics.com ↗
2024-12-10 Transcend Therapeutics TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth transcendtherapeutics.com ↗
2024-12-10 Transcend Therapeutics Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201 transcendtherapeutics.com ↗
2024-05-30 Transcend Therapeutics TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45) transcendtherapeutics.com ↗
2024-05-30 Transcend Therapeutics TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36) transcendtherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TSND-201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07456696 ↗
1

NCT07670702 ↗
Route Oral “TSND-201 capsules, given orally, once a week for four consecutive weeks” NCT07456696 ↗